Home
About
Disclaimer
Privacy

JCS/T2D - We are advocates. We learn. We share. We inform.

Enter Part of Title

Display #

About

Articles

Epigenetic Clues to Heart Risk in Type 2 Diabetes
Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss
Join the 5K@EASD Virtual Run/Walk for Diabetes Awareness 2024
Understanding the Link Between Type 2 Diabetes and Chronic Kidney Disease
Managing Blood Sugar with GLP-1 Medications: Foods to Avoid and Healthier Alternatives
The Surprising Mental Health Benefits of GLP-1 Medications for Diabetes and Obesity
New York Takes a Bold Step to Tackle Insulin Affordability
Addressing Misconceptions: A Closer Look at Weight Loss Drugs and Their Role in Managing Obesity and Type 2 Diabetes
Innovative Weight Loss Medication Shows Promise in Lowering Blood Pressure
Subtle Yet Significant Changes: The 2024 ADA Standards of Care in Diabetes
A New Era in Diabetes Management: Once-Weekly Insulin Icodec
Mounjaro: A New Player in the GLP-1 Arena for Type 2 Diabetes Management
The Economic Impact of Weight-Loss Drugs: A Trillion-Dollar Boost?
FDA Issues Alert on Compounded Semaglutide Dosing Errors
New Research Reveals the Hidden Complexity of Insulin Resistance
Bridging Data and Healthcare in the Nordics
FDA Approves Lilly's Tirzepatide for Obesity
Novo Nordisk Announces Positive Results in Phase 3a Trial of IcoSema, a Combination of Semaglutide and Insulin Icodec for Type 2 Diabetes
Promising Phase 2 Results: Eli Lilly's Tirzepatide Shows Potential Beyond Diabetes and Obesity
Mounjaro Shortage: A Challenge for Diabetes and Obesity Patients

News

October 2025

FDA Approves Novo Nordisk’s Oral Semaglutide for Heart Protection in Type 2 Diabetes
Innovent’s Mazdutide Outperforms Semaglutide in Head-to-Head Trial
Lilly’s Oral GLP-1 Outperforms Farxiga in Type 2 Diabetes Trial
Semaglutide’s Heart Benefits Extend Beyond Weight Loss
Terns Ends Development of Oral Obesity Drug After Phase 2 Results

September 2025

CVS Caremark Faces Lawsuit Over Dropping Zepbound
Dexcom Introduces Smart Basal at EASD 2025
Eli Lilly Narrows Focus for Oral GLP-1 Naperiglipron
Lilly’s Oral GLP-1, Orforglipron, Shows Strong Results in Obesity and Diabetes Trials
Novo Nordisk Resubmits Once-Weekly Basal Insulin Awiqli® for FDA Review
Novo Nordisk Survey Links Wegovy® to Reduced “Food Noise” and Improved Well-Being
Novonesis and Novo Nordisk Launch Gut Microbiome Collaboration

August 2025

FDA Approves Wegovy for MASH Treatment
FDA Expands Repatha Access to More High-Risk Adults
Lilly Advances Orforglipron Toward Approval After Third Phase 3 Win
Novo Nordisk Expands $499 Cash-Pay Option to Ozempic
Novo Nordisk Strikes $550M RNA Deal with Replicate Bioscience
Signos Press Release Raises Questions About FDA Clearance Claims
Teva Launches First Generic GLP-1 for Obesity
Wegovy Outperforms Mounjaro in Cardiovascular Outcomes

Top Subjects

Type 2 Diabetes
Novo Nordisk
Semaglutide
Obesity Treatment
GLP-1
Wegovy
Eli Lilly
Tirzepatide
Ozempic
Zepbound
Diabetes
Obesity
FDA Approval
Diabetes Management
Cardiovascular Health
Mounjaro
SELECT Trial
Continuous Glucose Monitoring
GLP-1 Therapy
Obesity Management
Metabolic Health
Orforglipron
Disease Modification
Dexcom
CGM
Rybelsus
Clinical Trials
Oral Semaglutide
FDA
Diabetes Treatment

Contact Us

How many eyes does a typical person have?

Search

Search

You are here:
Home
JCS/T2D - A Diabetes Journey

Copyright © 2025 JCS/T2D - A Diabetes Journey. All Rights Reserved.

Joomla! is Free Software released under the GNU General Public License.